Physician profile
Charles V Guida
NPI 1144288143
$1,046.94
in general payments reported to CMS, 2019-2025
15 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $91.23 · 2021: $266 · 2022: $146 · 2023: $190 · 2024: $91.63 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $240.25 | 2019-2025 | |
| Novo Nordisk INC | $239.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.86 | 2021-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $60.55 | 2023-2025 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $55.45 | 2021-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $47.73 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $42.16 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.05 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $33.95 | 2020-2023 | Farxiga |
| Neurocrine Biosciences, INC. | $29.01 | 2025 | |
| Shield Therapeutics INC | $27.33 | 2024 | |
| Allergan, INC. | $22.10 | 2019 | |
| Glaxosmithkline, LLC. | $20.04 | 2024 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $19.23 | 2020 | |
| Currax Pharmaceuticals LLC | $16.77 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Guida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.